240 results on '"Giannelli, V"'
Search Results
2. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels
3. Occurrence of Chronic Renal Failure in Liver Transplantation: Monitoring of Pre- and Posttransplantation Renal Function
4. Acute Renal Failure in Liver Transplant Recipients: Role of Pretransplantation Renal Function and 1-Year Follow-Up
5. The IMPROVEMENT project: first report of the global liver transplant activity
6. Conversion From Twice-Daily to Once-Daily Tacrolimus Administration in Liver Transplant Patient
7. Bone Disorders in Patients With Chronic Liver Disease Awaiting Liver Transplantation
8. Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy
9. Efficacy of lenvatinib in intermediate stage and advanced hepatocellular carcinoma: Results of monotherapy and combination with locoregional treatment
10. Nationwide survey of liver transplantation for Primary Sclerosing Cholangitis in Italy
11. Metabolic Syndrome and Cardiovascular Risk after Liver Transplantation: A Single-Center Experience
12. ULCERATIVE LICHEN PLANUS WITH AN UNUSUAL LICHENOID INFILTRATE MASQUERADING AS SECONDARY SYPHILIS
13. The forgotten ventricle: right ventricular (RV) evaluation in patients with cirrhosis listed for liver transplantation
14. SARS-CoV-2 infection in liver transplantation is associated with favorable outcomes: an Italian transplant registry study
15. Liver Transplant in Patient with Breast Cancer Liver Metastasis and Hepatic Failure
16. M555 UNRAVELING THE MYSTERY OF A PRURITIC RASH
17. Sarco-model, a novel score to better predict the risk of death in cirrhotic patients awaiting liver transplantation
18. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
19. SAT-003 - A functional metagenomics investigation of cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy
20. FRI-387 - Antiviral therapy can prevent in HCV infected patients relapse of diffuse large B cell lymphoma
21. FRI-379 - Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
22. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
23. Daclatasvir/sofosbuvir and ribavirin 800 mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience
24. SAT-014 - Decrease in cardiac work in patients with alcoholic hepatitis: role of inflammation?
25. FRI-481 - Prevalence of end of life criteria in patients with liver disease in South West England
26. PS062 - Prevalence of Cardiomyopathy and Impact of the use of Non Selective Beta Blockers in End-Stage Liver Disease
27. P0064 : Ribavirin pre-treatment in liver transplant patients with hcv recurrence: Results from pearl multicentre randomized trial
28. P473 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY
29. P41 DOES THE GUT MICROBIOTA MODULATE THE INFLAMMATORY STATE IN CIRRHOTIC HOST?
30. P.16.13 PROTEIN MALNUTRITION IS ASSOCIATED TO A WORSE PROGNOSIS IN PATIENTS WITH CIRRHOSIS CHILD A–B AND SEPSIS
31. Does the gut microbiota modulate the inflammatory state in cirrhotic host?
32. Italian survey on HBV and liver transplantation in a cohort of 2260 patients
33. Hydroxyurea-induced interstitial pneumonitis: case report and review of the literature.
34. 213 BETABLOCKERS AND A PROPER USE OF PROTON PUMP INHIBITORS MAY REDUCE THE RISK OF BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS
35. 197 FACTORS RELATED TO HOSPITALIZATION BUT NOT THE SEVERITY OF THE LIVER DISEASE INCREASE THE RISK OF NOSOCOMIAL INFECTION IN CIRRHOTIC PATIENTS
36. 158 RESPONSE PREDICTION IN CHRONIC HEPATITIS C AFTER LIVER TRANSPLANT BY ASSESSMENT ENT-1-RELATED SINGLE NUCLEOTIDE POLYMORPHISMS
37. 157 BONE DISORDERS BEFORE AND AFTER LIVER TRANSPLANTATION
38. T-35 Cirrhotic patients fail to regain muscle mass after liver transplantation
39. OC-20 Prophylaxis of hepatitis B after liver transplantation: report of an Italian survey in a cohort of 2260 patients
40. O9 BACTERIAL INFECTIONS INDUCE BOTH OVERT AND MINIMAL HEPATIC ENCEPHALOPATHY: RESULTS OF A PROSPECTIVE STUDY
41. O8 RISK FACTORS FOR NOSOCOMIAL INFECTION IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY
42. O3 THE IMPACT OF MALNUTRITION ON THE OUTCOME OF CIRRHOTIC PATIENTS WITH INFECTIONS
43. 589 OXIDATIVE STRESS AND INFLAMMATION IN LIVER CIRRHOSIS: ROLE OF N-6/N-3 POLYUNSATURATED FATTY ACIDS BALANCE
44. 164 POST-TRANSPLANTATION METABOLIC SYNDROME: IS IT ONLY A THERAPEUTIC CONCERN?
45. P.04.9 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
46. P.04.4 SVR TO ANTIVIRAL TREATMENT FOR POST-OLT RECURRENT HCV HEPATITIS CAN BE IMPROVED BY THE USE OF GROWTH FACTORS
47. P.03.14 COMBINED THERAPY WITH LOW DOSE HEPATITIS B IMMUNOGLOBULIN AND LAMIVUDINE IN PATIENTS TRANSPLANTED FOR HBV END STAGE LIVER DISEASE: STILL COST-EFFECTIVE?
48. P.03.6 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
49. 579 THE PRESENCE OF DIABETES REDUCES SVR AFTER ANTIVIRAL THERAPY FOR POST-TRANSPLANT HCV RECURRENCE
50. 578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.